Adults younger than 50 years had on average a higher CD4 increase of 45 cells per cubic millimeter (95% confidence interval: 17 to 72; = 0.001) compared with counterparts aged 60 years and older; mortality was highest among older adults compared with younger counterparts
Immunologic and clinical responses to HAART in patients over 50 years old
CD4 mean increase during the first 6 months on HAART was +42.9 × 106 cells/L per month in patients under 50 years and +36.9 × 106 cells/L per month in patients over 50 years ( < 0.0001) Older patients had a significantly higher risk of clinical progression (hazard ratio (HR) = 1.52 [95% confidence interval (CI), 1.15–2.00])
The adjusted hazard ratios (HRs) for all-cause mortality increased with increasing age Older patients were less likely to increase their CD4 count by ≥50 cells/mm